All data are based on the daily closing price as of June 27, 2025
h

Hanmi Pharm. Co.

128940.KO
213.13 USD
-1.01
-0.47%

Overview

Last close
213.13 usd
Market cap
2.70B usd
52 week high
258.79 usd
52 week low
146.58 usd
Target price
261.05 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
2.4757
Price/Book Value
3.2943
Enterprise Value
2.88B usd
EV/Revenue
2.6469
EV/EBITDA
14.5365

Key financials

Revenue TTM
1.09B usd
Gross Profit TTM
589.40M usd
EBITDA TTM
214.39M usd
Earnings per Share
N/A usd
Dividend
0.92 usd
Total assets
1.35B usd
Net debt
N/A usd

About

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
  • Symbol
    128940.KO
  • Exchange
    KO
  • Isin
    KR7128940004
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Jae-Hyun Park
  • Headquarter
    Hwaseong-si
  • Web site
    https://www.hanmipharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top